KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Non-Current Assets (2018 - 2025)

Twist Bioscience (TWST) has disclosed Non-Current Assets for 8 consecutive years, with $334.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 26.94% to $334.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Dec 2025, up 5.8% year-over-year, with the annual reading at $308.9 million for FY2025, 15.45% up from the prior year.
  • Non-Current Assets for Q4 2025 was $334.2 million at Twist Bioscience, up from $308.9 million in the prior quarter.
  • The five-year high for Non-Current Assets was $401.2 million in Q4 2021, with the low at $69.3 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $299.3 million, with a median of $332.6 million recorded in 2024.
  • The sharpest move saw Non-Current Assets surged 515.82% in 2021, then dropped 24.26% in 2024.
  • Over 5 years, Non-Current Assets stood at $401.2 million in 2021, then decreased by 8.24% to $368.1 million in 2022, then dropped by 6.93% to $342.6 million in 2023, then dropped by 23.15% to $263.3 million in 2024, then increased by 26.94% to $334.2 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $334.2 million, $308.9 million, and $303.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.